{
  "title": "test table 2",
  "slices": [
    {
      "filter": {
        "name": "Elunate and Key Competitors DOT/CASH Performance in CHPA (MAT)",
        "description": "from display and timeline",
        "factory": "com.pharbers.process.stm.step.pptx.filter.phSearchFilterImpl",
        "filt": []
      },
      "sliders": [
        {
          "title": "Prozac and Key Competitors DOT Trends in CHPA",
          "content": {
            "factory": "com.pharbers.process.stm.step.pptx.slider.content.phReportContentImpl",
            "texts": [
              {
                "pos": [
                  0, 0, 100, 100
                ],
                "font": "",
                "text": ""
              }
            ],
            "tables": [
              {
                "factory": "com.pharbers.process.stm.step.pptx.slider.content.phReportContentTrendsTable",
                "mkt_display": "Total Rapid Analog",
                "mkt_col": "MMU",
                "pos": [
                  50, 50, 81, 81
                ],
                "timeline": [
                  "M09 18:timeline_2", "M08 17:timeline_2","M07 17:timeline_2","M06 17:timeline_2","M05 17:timeline_2","M04 17:timeline_2",
                  "M03 17:timeline_2","M02 17:timeline_2","M01 17:timeline_2","M09 17:timeline_2","M09 17:timeline_2","M09 17:timeline_2",
                ],
                "col": {
                  "title" : ":row_6",
                  "count" : [
                    "SOM(%):col_common"
                  ]
                },
                "row": {
                  "title" : ":col_som",
                  "display_name" : [
                    "Total mCRC 3L Market (Relevant):row_6","AI HENG            JSH:row_6",
                    "ELOXATIN           SG9:row_6","Other Oxaliplatin:row_2","XELODA             ROC:row_6"
              ]
                }
              }
            ]
          }
        }
      ]
    }
  ]
}